Phibro Animal Health (Phibro Animal Health) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Phibro Animal Health is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Phibro Animal Health's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phibro Animal Health's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Risk Assessment falls into.

Phibro Animal Health (NAS:PAHC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Phibro Animal Health Risk Assessment Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Phibro Animal Health (Phibro Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

PB8:Germany

Address

300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712

Website

https://www.pahc.com

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Executives

Judith Weinstein	officer: See Remarks	C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran	director
Larry Lee Miller	officer: Chief Operating Officer	8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio	officer: Chief Financial Officer	C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman	officer: President,North America Region	C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim	director, officer: Exec. VP, Corporate Strategy	300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras	officer: Pres Animal Health & Nutr N.A.	5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim	director, 10 percent owner, officer: President and CEO	C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc	10 percent owner	300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim	director	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino	officer: SEE REMARKS	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson	officer: Chief Financial Officer	7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson	director	2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger	officer: SVP, Gen Counsel and Corp Sec	41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046